Eylea 2 MG/0.05 ML syringe 0.05ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQWL1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $28,674
Award facts
- Contract value 100% obligated
- $28,674.24 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $28.67K delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of EYLEA 2 mg/0.05 mL syringes. The contract is firm fixed-price with no set-aside designation and carries an ultimate completion date of February 5, 2026. Performance will occur at the vendor's Park Ridge location. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (SPE2DR) established under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to supply pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated consistent performance as a critical supplier within the federal pharmaceutical supply chain, with numerous delivery orders spanning branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables. The company's IDC, which was awarded on November 13, 2025, features a $499.999 billion ceiling value with a 30-month base period and three 30-month option periods extending through December 31, 2036. Under this vehicle, the Defense Logistics Agency maintains the flexibility to issue firm fixed-price delivery orders for recurring medical supply needs across the military healthcare system, leveraging DMS Pharmaceutical Group's established capability to fulfill diverse and specialized pharmaceutical requirements supporting Department of Defense operations globally.
Quick answers
Who was awarded contract SPE2DR26FQWL1?
SPE2DR26FQWL1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 14, 2026.
How much is contract SPE2DR26FQWL1 worth?
The government has obligated $28,674 on SPE2DR26FQWL1.
Is contract SPE2DR26FQWL1 an order under another contract?
Yes. SPE2DR26FQWL1 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWL1 competed?
The extent of competition for SPE2DR26FQWL1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award